Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 5/20 | 0.84 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.84 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.84 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.37 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359532 | 0.91 | BCL2 (1.00) | BCL2BCL2L1MCL1SIRT5ALDH1A1 | |
| SCHEMBL29360605 | 0.91 | BCL2 (1.00) | BCL2BCL2L1MCL1SIRT5ALDH1A1 | |
| SCHEMBL687266 | 0.91 | BCL2 (1.00) | BCL2BCL2L1MCL1SIRT5ALDH1A1 | |
| SCHEMBL22781207 | 0.86 | BCL2 (0.87) | BCL2BCL2L1MCL1SIRT5ALDH1A1 | |
| SCHEMBL15313829 | 0.82 | BCL2 (0.80) | BCL2BCL2L1MCL1SIRT5ALDH1A1 | |
| SCHEMBL15313819 | 0.82 | BCL2 (0.79) | BCL2BCL2L1MCL1SIRT5ALDH1A1 | |
| SCHEMBL15313802 | 0.81 | BCL2 (0.75) | BCL2BCL2L1MCL1SIRT5AVPR2 | |
| SCHEMBL15313827 | 0.80 | BCL2 (0.64) | BCL2BCL2L1MCL1SIRT5AVPR2 | |
| SCHEMBL15313821 | 0.80 | BCL2 (0.79) | BCL2BCL2L1MCL1SIRT5LMNA | |
| SCHEMBL15313823 | 0.79 | BCL2 (0.72) | BCL2BCL2L1MCL1SIRT5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | GILEAD SCIENCES, INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | BCL2, BAK1, BRD4 | BCL2 1/4885BCL2L1 6/4885MCL1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.